{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:45:53Z","timestamp":1793666753392,"version":"4.5.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the long-term efficacy of once-daily baricitinib 4\u2009mg or 2\u2009mg in patients with active rheumatoid arthritis who had inadequate response (IR) to MTX, csDMARDs or bDMARDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from three completed phase III studies\u2014RA-BEAM (MTX-IR), RA-BUILD (csDMARD-IR) and RA-BEACON (bDMARD-IR)\u2014and one completed long-term extension study (RA-BEYOND) were analysed up to 6.5\u2009years [340\u2009weeks (RA-BEAM) and 336\u2009weeks (RA-BUILD and RA-BEACON)]. Low disease activity (LDA) [Simplified Disease Activity Index (SDAI) \u226411], clinical remission (SDAI \u22643.3) and physical function [Health Assessment Questionnaire Disability Index (HAQ-DI) \u22640.5] were the main outcomes assessed. Completer and non-responder imputation (NRI) analyses were conducted on each population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 340 or 336, LDA was achieved in 37%\/83% of MTX-IR, 35%\/83% of csDMARD-IR and 23%\/73% of bDMARD-IR patients treated with baricitinib 4\u2009mg, assessed by NRI\/completer analyses, respectively. Remission was achieved in 20%\/40% of MTX-IR, 13%\/32% of csDMARD-IR and 9%\/30% of bDMARD-IR patients treated with baricitinib 4\u2009mg, assessed by NRI\/completer analyses, respectively. HAQ-DI \u22640.5 was reached in 31%\/51% of MTX-IR, 25%\/46% of csDMARD-IR and 24%\/38% of bDMARD-IR patients treated with baricitinib 4\u2009mg, assessed by NRI\/completer analyses, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment with baricitinib 4\u2009mg or 2\u2009mg demonstrated efficacy up to 6.5\u2009years with maintained LDA\/remission results across SDAI, CDAI and DAS28-hsCRP consistent with previously reported data, and was well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>United States National Library of Medicine clinical trials database www.clinicaltrials.gov; RA-BEYOND; NCT01885078.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae012","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T08:13:09Z","timestamp":1705997589000},"page":"2799-2809","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-8559","authenticated-orcid":false,"given":"Roberto","family":"Caporali","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Universit\u00e0 degli Studi di Milano and ASST Gaetano Pini CTO , Milano,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimon","family":"Sanmart\u00ed","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Cl\u00ednic de Barcelona and IDIBAPS , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo and Saitama Medical University , Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojun","family":"Mo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Haladyj","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bello","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Zaremba-Pechmann","sequence":"additional","affiliation":[{"name":"HaaPACS GmbH , Schriesheim,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Cochin Hospital, APHP, Paris and INSERM U-1153, CRESS Paris-Sorbonne , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"2024100107523414800_keae012-B1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2024100107523414800_keae012-B2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/BOR.0000000000000267","article-title":"Comorbidities in rheumatoid arthritis","volume":"28","author":"Dougados","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2024100107523414800_keae012-B3","first-page":"107","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024100107523414800_keae012-B4","year":"2020"},{"key":"2024100107523414800_keae012-B5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024100107523414800_keae012-B6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"2024100107523414800_keae012-B7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024100107523414800_keae012-B8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2024100107523414800_keae012-B9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024100107523414800_keae012-B10","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/rheumatology\/keaa576","article-title":"Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study","volume":"60","author":"Smolen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024100107523414800_keae012-B11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40744-021-00317-9","article-title":"Efficacy of long-term treatment with once-daily baricitinib 2 mg in patients with active rheumatoid arthritis: post hoc analysis of two 24-week, phase III, randomized, controlled studies and one long-term extension study","volume":"8","author":"Wells","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2024100107523414800_keae012-B12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials","volume":"70","author":"David","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024100107523414800_keae012-B13","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/annrheumdis-2013-204948","article-title":"Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology","volume":"74","author":"Buch","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024100107523414800_keae012-B14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s40744-023-00597-3","article-title":"Comparative effectiveness, time to discontinuation, and patient-reported outcomes with baricitinib in rheumatoid arthritis: 2-year data from the multinational, prospective observational RA-BE-REAL study in European patients","volume":"10","author":"Alten","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2024100107523414800_keae012-B15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2024100107523414800_keae012-B16","doi-asserted-by":"crossref","first-page":"e000935","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study","volume":"5","author":"Mehta","year":"2019","journal-title":"RMD Open"},{"key":"2024100107523414800_keae012-B17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s13075-014-0435-y","article-title":"A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases","volume":"16","author":"Lee","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2024100107523414800_keae012-B18","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","article-title":"Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study","volume":"39","author":"Ogdie","year":"2018","journal-title":"Eur Heart J"},{"key":"2024100107523414800_keae012-B19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40744-019-00189-0","article-title":"Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis","volume":"7","author":"DeMizio","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024100107523414800_keae012-B20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","article-title":"Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study","volume":"37","author":"van den Hoek","year":"2017","journal-title":"Rheumatol Int"},{"key":"2024100107523414800_keae012-B21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024100107523414800_keae012-B22","doi-asserted-by":"crossref","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"2024100107523414800_keae012-B23","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","article-title":"Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis","volume":"2","author":"Genovese","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2024100107523414800_keae012-B24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae012\/56609660\/keae012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/10\/2799\/59432434\/keae012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/10\/2799\/59432434\/keae012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T07:53:39Z","timestamp":1727769219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/10\/2799\/7585442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,1,22]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae012","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,1,22]]}}}